BlossomHill Q2 net loss $23.8M; IPO raises $168.3M; FDA Fast Track for lung cancer drug

BlossomHill Therapeutics, Inc.

Q2 2026 net loss $23.8M ($8.75/share) vs $13.2M ($5.51/share) in Q2 2025.
R&D expenses $21.4M (up from $12.5M); G&A $3.3M (up from $1.6M).
Cash $95.4M at June 30; August IPO gross proceeds $168.3M fund ops into Q2 2028.
FDA Fast Track granted for BH-30643 in EGFR C797S-positive NSCLC after 3rd-gen TKI.
Phase 1 SOLARA data: 45% ORR, 88% DCR in C797S-resistant patients; more milestones ahead.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.